Observational analysis reports the need for drug withdrawal in cases of significant adverse effects, highlighting the role of pharmacovigilance.
Pharmacovigilance is concerned with the adverse effects of the authorized drugs after use, hence if the adverse effects are harmful and deteriorate other organs or tissues of the patient. These adverse effects were reported by the patients, pharmacists, nurses, clinicians, and physicians. Some examples which withdrawal from the markets according to the pharmacovigilance: astemizole, cisapride, terfenadine, and rofecoxib, which revealed many adverse effects leading to their withdrawal these drugs from the markets. Aim of the research: The knowledge around pharmacovigilance and improving the side effects of drugs which present in the market, the results of this improvement led us to obtain new drugs without serious side effects. We conclude that the market drugs improved from the older drugs, have side effects will are suitable to the usage by patients.
No takes yet. Share an insight, caveat, or question.
Asokan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: